Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
Summary
This open label phase II study is evaluating the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer as a first-line treatment. The objective of the study is to evaluate the safety, tolerability, toxicity and efficacy of this combination therapy.
General Information
NCT#: NCT02340117
Study ID: SGT53-02-1
Trial Phase: Phase II
Trial Sponsor: SynerGene Therapeutics, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, SGT-53